Inhibition of Parkinson’s disease–related LRRK2 by type I and type II kinase inhibitors: Activity and structures

Mutations in leucine-rich repeat kinase 2 (LRRK2) are a common cause of familial Parkinson’s disease (PD) and a risk factor for the sporadic form. Increased kinase activity was shown in patients with both familial and sporadic PD, making LRRK2 kinase inhibitors a major focus of drug development effo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanz Murillo, Marta, Villagran Suarez, Amalia, Dederer, Verena, Chatterjee, Deep, Alegrio Louro, Jaime, Knapp, Stefan, Mathea, Sebastian, Leschziner, Andres E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2023
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691770/
https://www.ncbi.nlm.nih.gov/pubmed/38039358
http://dx.doi.org/10.1126/sciadv.adk6191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691770/
https://www.ncbi.nlm.nih.gov/pubmed/38039358
http://dx.doi.org/10.1126/sciadv.adk6191

Ejemplares similares